M a t r i x M e t a l l o p r oteinase I nhibitor C OL-3 i n t he Treatment o f A IDS-Related K aposi's S arcoma: A P hase I AIDS M alignancy C onsortium S tudy
Mary Cianfrocca(Northwestern University), Bruce J. Dezube(Xilio Therapeutics (United States)), James M. Pluda(Center for Cancer Research), Jeannette Y. Lee(University of Arkansas at Little Rock), Lee Ratner(Washington University in St. Louis), Michelle A. Rudek(Dana-Farber Cancer Institute), Timothy P. Cooley(Memorial Sloan Kettering Cancer Center), David T. Scadden(Harvard University), William D. Figg(National Cancer Institute), Susan E. Krown(Memorial Sloan Kettering Cancer Center)
Unknown
January 1, 2002
Cited by 0
Related Papers
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
|Journal of Clinical Oncology|2014|714
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707